Major outcomes with NIH chronic GVHD compared with late acute GVHD at onset
| Outcome . | Unadjusted hazard ratio (95% CI) . | Adjusted hazard ratio (95% CI)* . |
|---|---|---|
| Nonrelapse mortality | 1.02 (0.8-1.3) | 0.87 (0.6-1.2) |
| Recurrent malignancy | 0.76 (0.6-1.1) | 0.98 (0.7-1.5) |
| Overall mortality | 0.92 (0.7-1.1) | 0.84 (0.6-1.1) |
| Discontinued systemic treatment | 0.91 (0.7-1.1) | 1.09 (0.8-1.4) |
| Outcome . | Unadjusted hazard ratio (95% CI) . | Adjusted hazard ratio (95% CI)* . |
|---|---|---|
| Nonrelapse mortality | 1.02 (0.8-1.3) | 0.87 (0.6-1.2) |
| Recurrent malignancy | 0.76 (0.6-1.1) | 0.98 (0.7-1.5) |
| Overall mortality | 0.92 (0.7-1.1) | 0.84 (0.6-1.1) |
| Discontinued systemic treatment | 0.91 (0.7-1.1) | 1.09 (0.8-1.4) |
In these models, transition from late acute GVHD at onset to NIH chronic GVHD was not considered as a competing risk.
The adjusted analysis accounts for the effects of de novo, quiescent or progressive onset, prednisone dose at onset, platelet count at onset, prior acute GVHD before day 100, patient age, donor age, number of HLA mismatches, female donors for male recipients, mobilized blood cell grafts, transplantation year, or number of organs affected by GVHD at onset.